London-based Tuune, a femtech startup that leverages AI and biological testing to match women with the most suitable contraception option, announced that it has bagged $4.6M (approx €3.98M) in a fresh round of funding led by venture capital firm Octopus Ventures.
The proceeds from this round will help the company to launch its product in the US market. The funds will also enable Tuune to build a more individualised medical system that puts hormones first, and claims it will transform the future of healthcare for all women and people with cycles.